Comprehensive medication guide to Adlyxin Starter Kit including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
Adlyxin is no longer covered by insurance because it has been discontinued in the US. Patients previously on Adlyxin should ask their doctor about switching to a covered GLP-1 alternative such as Ozempic or Trulicity.
Estimated Cash Pricing
The Adlyxin Starter Kit was discontinued in the US as of January 1, 2023. Before discontinuation, retail cash price was approximately $675–$757 per pack at major pharmacies. No new supply is available.
Medfinder Findability Score
5/100
Summarize with AI
On this page
The Adlyxin Starter Kit was a two-pen initiation package for adults beginning lixisenatide therapy for type 2 diabetes mellitus. It contained one green prefilled pen (50 mcg/mL; 14 doses of 10 mcg for the first 14 days) and one burgundy prefilled pen (100 mcg/mL; 14 doses of 20 mcg for days 15–28), together providing a full 28-day supply. Manufactured by Sanofi, Adlyxin (lixisenatide) was FDA-approved in July 2016 as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Important update: Sanofi permanently discontinued Adlyxin in the United States as of January 1, 2023. Adlyxin is not available at US pharmacies and is not expected to return to the market. Lixisenatide is still available in the US as part of Soliqua 100/33 (insulin glargine/lixisenatide), which remains on the market.
Patients who were taking Adlyxin should consult their healthcare provider to transition to an appropriate GLP-1 receptor agonist alternative. Several effective options are available, including once-weekly semaglutide (Ozempic), dulaglutide (Trulicity), and once-daily liraglutide (Victoza).
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Lixisenatide is a GLP-1 receptor agonist — a synthetic 44-amino acid peptide that activates the same receptors as the naturally occurring hormone GLP-1 (glucagon-like peptide-1). It acts through three primary mechanisms to lower blood glucose in type 2 diabetes.
Glucose-dependent insulin stimulation: Lixisenatide triggered the pancreas to release more insulin, but only when blood glucose was already elevated — reducing hypoglycemia risk.
Glucagon suppression: It suppressed post-meal glucagon release, reducing the liver's contribution to rising blood sugar after eating.
Potent gastric emptying inhibition: Lixisenatide's most distinctive mechanism was substantially slowing gastric emptying, which blunted the post-meal glucose spike. This was more pronounced than in long-acting weekly GLP-1 agents, but also caused more nausea. Lixisenatide has approximately 4-fold greater affinity for the GLP-1 receptor than native human GLP-1.
10 mcg — subcutaneous injection (green starter pen)
Starting dose for days 1–14; 50 mcg/mL concentration; 14 doses per pen
20 mcg — subcutaneous injection (burgundy pen)
Maintenance dose from day 15 onward; 100 mcg/mL concentration; 14 doses per pen
The Adlyxin Starter Kit is impossible to find at US pharmacies — not because of a temporary shortage, but because Sanofi permanently discontinued lixisenatide in the United States as of January 1, 2023. This was a voluntary market withdrawal driven by competition from newer GLP-1 agents and poor financial performance.
No US pharmacy is receiving new Adlyxin supply. Calling pharmacies to check stock will not yield positive results. The only lixisenatide-containing product still available in the US is Soliqua 100/33 (insulin glargine/lixisenatide), which remains on the market for patients requiring both basal insulin and GLP-1 coverage.
If you are looking for Soliqua or any GLP-1 alternative, medfinder can call pharmacies in your area to find which ones have your specific replacement medication in stock.
Lixisenatide (Adlyxin) was not a controlled substance and had no DEA scheduling restrictions. Any licensed prescriber with prescribing authority could write for it. The same applies to all current GLP-1 receptor agonist alternatives for type 2 diabetes.
Endocrinologists — Specialists in diabetes; manage complex or difficult-to-control type 2 diabetes
Primary Care Physicians (PCPs) — Family medicine and internal medicine doctors routinely prescribe GLP-1 agents
Nurse Practitioners (NPs) and Physician Assistants (PAs) — Have independent or collaborative prescribing authority in most US states
Cardiologists — May prescribe GLP-1 agents for patients with established cardiovascular disease and T2DM
Telehealth platforms are widely available for type 2 diabetes management in 2026, including Teladoc, MDLive, and specialized metabolic health services. Providers on these platforms can evaluate diabetes, review lab results, and prescribe GLP-1 alternatives without an in-person visit.
No. Adlyxin (lixisenatide) was not a controlled substance and was not scheduled by the DEA. It required a standard prescription but had no special prescribing restrictions, quantity limits, or scheduling requirements associated with controlled substances.
The same applies to all currently available GLP-1 receptor agonist alternatives, including semaglutide (Ozempic), dulaglutide (Trulicity), liraglutide (Victoza), tirzepatide (Mounjaro), and Soliqua 100/33. These medications do not require a DEA controlled substance prescription and can be prescribed by any licensed healthcare provider with prescribing authority.
The following side effects occurred in 5% or more of patients in clinical trials (n=2,869):
Nausea (most common; improves over 2–4 weeks)
Vomiting
Headache
Diarrhea
Dizziness
Hypoglycemia (particularly with concurrent sulfonylureas or insulin)
Anaphylaxis / severe allergic reaction (0.2% incidence; stop medication and call 911)
Acute pancreatitis (severe persistent abdominal pain; do not restart if confirmed)
Acute kidney injury (can occur with severe GI side effects causing dehydration)
Severe hypoglycemia (blood glucose <36 mg/dL; especially when combined with sulfonylurea or basal insulin)
Know what you need? Skip the search.
Soliqua 100/33 (insulin glargine/lixisenatide)
Still contains lixisenatide; combines basal insulin and GLP-1 in one daily injection; available in US; indicated for T2DM inadequately controlled on basal insulin <60 units/day
Ozempic (semaglutide)
Once-weekly GLP-1; stronger A1C reduction (1.0–1.8%) and weight loss (3–6 kg) vs lixisenatide; proven cardiovascular benefit; most prescribed GLP-1 in the US
Trulicity (dulaglutide)
Once-weekly GLP-1 with hidden-needle auto-injector; cardiovascular outcome data (REWIND); available in doses 0.75–4.5 mg weekly
Victoza (liraglutide)
Once-daily GLP-1; closest dosing frequency to Adlyxin; proven cardiovascular benefit (LEADER trial); long safety record since 2010
Prefer Adlyxin Starter Kit? We can find it.
Sulfonylureas (glimepiride, glipizide)
majorIncreased hypoglycemia risk (14.5% vs 10.6% placebo); dose reduction of sulfonylurea often required
Basal insulin
majorIncreased hypoglycemia risk (47.2% vs 21.6% placebo); insulin dose reduction frequently needed
Oral contraceptives
moderateDelayed absorption; take at least 1 hour before or 11 hours after lixisenatide injection
Oral antibiotics and threshold-dependent medications
moderateDelayed absorption due to gastric slowing; take at least 1 hour before lixisenatide injection
Acetaminophen
minorCmax decreased 29–31% when taken 1–4 hours after lixisenatide; no effect on AUC; take before injection if prompt pain relief needed
Digoxin
minorTmax delayed by 1.5 hours; AUC unaffected
Ramipril
minorAUC increased 21%; Cmax decreased 63%; active metabolite (ramiprilat) unaffected
The Adlyxin Starter Kit (lixisenatide) was a well-designed initiation product for a GLP-1 receptor agonist that, while effective for postprandial glucose control, could not survive the competitive disruption brought by once-weekly semaglutide and tirzepatide. The January 2023 US market withdrawal was a business decision by Sanofi, not a safety recall, and patients with type 2 diabetes have access to superior alternatives today.
If you were on the Adlyxin Starter Kit, contact your doctor to discuss transitioning to an appropriate GLP-1 agent. Soliqua 100/33 remains available if you need both lixisenatide and basal insulin in a single injection. For patients who want standalone GLP-1 therapy, Ozempic (semaglutide), Trulicity (dulaglutide), and Victoza (liraglutide) are evidence-based alternatives with strong safety records.
Once your doctor prescribes a replacement, medfinder can help you locate it in stock at pharmacies near you, saving you the frustration of calling around yourself.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini